CML increases the acetylation of NFATc1 at the K549 site by inhibiting the deacetylase SIRT3 and antagonizing focal adhesion kinase (FAK). This evidence concerns the gene NFATC1 and chronic myelogenous leukemia, BCR-ABL1 positive.